The Center for Research in Inflammatory Diseases (CRID) was created with the aim of producing integrative and translational scientific research to identify and validate new biological pathways involved in the induction and resolution of inflammation. To this end, it counts on the experience of researchers from various fields of Biomedical Sciences linked to basic research (genetics, molecular and cell biology, immunology, pharmacology, and pathology) and clinical research (rheumatology, immunology, infectology, and dermatology), in addition to researchers in the area of bioinformatics.
Inflammatory diseases constitute a complex and heterogeneous group of diseases that affect more than 10% of the world population. The treatment alternatives currently available are limited and, in some cases, ineffective, considering that information on the underlying mechanisms of the inflammatory process and the pathophysiology of inflammatory diseases is still lacking.
The specific objective of the Center is to advance knowledge about inflammatory diseases (infectious, autoimmune, and related to the cardiovascular system) to recognize and understand the molecular, immunological, pathological, and pharmacological mechanisms involved; identify new biological targets for the development of pharmacological therapeutic tools; search for possible diagnostic markers and prognostic indications, and apply new knowledge to design and synthesize molecules aimed at treating inflammatory diseases.
In a study of the effects of cigarette smoking on exacerbation of the disease, scientists at a FAPESP-supported research center identified a novel pathway in the inflammatory process relating to bone damage.
Pro-Vaccine Union, an initiative of the University of São Paulo in partnership with other organizations including Research, Innovation and Dissemination Centers funded by FAPESP, is monitoring anti-vaccine groups on Facebook in an effort to understand the workings of the social media ecosystem that spreads disinformation.
In defense cells from patients hospitalized with the disease, Brazilian researchers found signs of activation of a protein complex called the inflammasome, responsible for initiating the inflammatory response that can damage organs and lead to death. The findings could help identify drugs capable of interrupting the process.
Led by research groups from the universities of Campinas and São Paulo, the investigation combined MRI scans of mild COVID-19 patients, analysis of brain tissue samples from patients who died from COVID-19, and experiments performed with human nerve cells infected in the laboratory.
In an article published in the Journal of Experimental Medicine, a group affiliated with a FAPESP-supported research center reports that an enzyme associated with energy production in cells also participates in the differentiation of immune cells involved in exacerbated inflammation. The discovery could lead to more effective treatment.
Researchers affiliated with institutions in Brazil and elsewhere analyzed blood work from almost 179,000 people who were tested for the novel coronavirus. They obtained the data from COVID-19 Data Sharing/BR, an open-access repository established by FAPESP.